Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-085 Phase 2 in Moderate to Severe Plaque Psoriasis
NCT02762994Phase 2Completed
- Sponsor
- BIOCAD
- Start
- Jun 2016
- Primary completion
- May 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of netakimab in plaque psoriasis (4 arms), sponsored by BIOCAD. Primary endpoint: Psoriasis Area and Severity Index 75 Response at 12 weeks. Started Jun 2016; status: completed.
02
Drugs
netakimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02762994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02762994.